(NASDAQ: TKNO) Alpha Teknova's forecast annual revenue growth rate of 26.98% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 10.12%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.2%.
Alpha Teknova's revenue in 2024 is $36,684,000.On average, 1 Wall Street analysts forecast TKNO's revenue for 2024 to be $1,498,218,303, with the lowest TKNO revenue forecast at $1,498,218,303, and the highest TKNO revenue forecast at $1,498,218,303. On average, 2 Wall Street analysts forecast TKNO's revenue for 2025 to be $2,110,569,108, with the lowest TKNO revenue forecast at $1,918,699,189, and the highest TKNO revenue forecast at $2,302,439,027.
In 2026, TKNO is forecast to generate $3,939,456,846 in revenue, with the lowest revenue forecast at $3,939,456,846 and the highest revenue forecast at $3,939,456,846.